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Abstract
BACKGROUND
Pluripotent stem cell-derived cardiomyocytes (CMs) have become one of the
most attractive cellular resources for cell-based therapy to rescue damaged
cardiac tissue.
AIM
We investigated the regenerative potential of mouse embryonic stem cell (ESC)-
derived platelet-derived growth factor receptor-α (DGFRα)+ cardiac lineage-
committed cells (CLCs), which have a proliferative capacity but are in a
morphologically and functionally immature state compared with differentiated
CMs.
METHODS
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We induced mouse ESCs into PDGFRα+ CLCs and αMHC+ CMs using a
combination of the small molecule cyclosporin A, the rho-associated coiled-coil
kinase inhibitor Y27632, the antioxidant Trolox, and the ALK5 inhibitor EW7197.
We implanted PDGFRα+ CLCs and differentiated αMHC+ CMs into a myocardial
infarction (MI) murine model and performed functional analysis using
transthoracic echocardiography (TTE) and histologic analysis.
RESULTS
Compared with the untreated MI hearts, the anterior and septal regional wall
motion and systolic functional parameters were notably and similarly improved
in the MI hearts implanted with PDGFRα+ CLCs and αMHC+ CMs based on TTE.
In histologic analysis, the untreated MI hearts contained a thinner ventricular
wall than did the controls, while the ventricular walls of MI hearts implanted
with PDGFRα+ CLCs and αMHC+ CMs were similarly thicker compared with that
of the untreated MI hearts. Furthermore, implanted PDGFRα+ CLCs aligned and
integrated with host CMs and were mostly differentiated into α-actinin+ CMs,
and they did not convert into CD31+ endothelial cells or αSMA+ mural cells.
CONCLUSION
PDGFRα+ CLCs from mouse ESCs exhibiting proliferative capacity showed a
regenerative effect in infarcted myocardium. Therefore, mouse ESC-derived
PDGFRα+ CLCs may represent a potential cellular resource for cardiac
regeneration.
Key words: Pluripotent stem cell; Embryonic stem cell; Cardiomyocyte; Myocardial
infarction; Regeneration
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: We demonstrated that mouse embryonic stem cell-derived platelet-derived
growth factor receptor-α+ cardiac lineage-committed cells have proliferative capacity but
are in a morphologically and functionally immature state compared with differentiated
cardiomyocytes; these cells exerted a regenerative effect on infarcted myocardium.
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INTRODUCTION
Myocardial infarction (MI) and heart failure are the most common causes of death in
patients with cardiovascular disease[1]. Despite remarkable advances in therapeutic
strategies for heart failure, such as novel drugs, ventricular assist device implantation,
and  heart  transplantation,  the  burden  of  the  disease  remains  high.  Cardiac
regeneration using stem cell therapy is an attractive therapeutic strategy to rescue
damaged cardiac tissue[2]. Among stem cell populations, pluripotent stem cells (PSCs)
such as embryonic stem cells  (ESCs) and induced pluripotent stem cells  (iPSCs),
exhibit a higher efficacy in cardiomyocyte induction and expansion rate compared
with adult stem cells[2].  Indeed, previous large numbers of reports demonstrated
functional improvement of damaged myocardium in murine, rodent, and porcine MI
models that received PSC-derived cardiomyocytes (CMs)[2-4].
However, the proliferative capacity of PSC-derived CMs is decreased after beating
and terminal differentiation[5].  Furthermore, there is no definite surface marker of
differentiated PSC-derived CMs to facilitate purification[6]. Recently, several studies
have been conducted to identify a novel marker for cardiac progenitor or cardiac
lineage-committed  cells  (CLCs),  which  are  intermediate-stage  cells  between
mesodermal cells and differentiated CMs with proliferative capacity[7-10]. Our group
previously established a novel class of cells from PSCs-platelet-derived growth factor
receptor-α (PDGFRα)+ CLCs-induced using a combination of four specific modulators:
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the mitochondrial permeability transition pore inhibitor cyclosporin A (CsA), the
ROCK inhibitor Y27632, the antioxidant Trolox, and the activin A receptor type II-like
kinase (ALK5) inhibitor EW7197 (collectively referred to here as CsAYTE)[11]. This
novel population of actively proliferating cells is cardiac lineage-committed but in a
morphologically  and functionally  immature  state  compared with  differentiated
CMs[11].  In the present study, we investigated the regenerative potential of mouse
ESC-derived PDGFRα+ CLCs in a murine MI model and compared their efficacy with
differentiated CMs.
MATERIALS AND METHODS
Mouse ESCs and OP9 cell culture
EMG7 mouse ESCs,  which have an αMHC promoter-driven enhanced GFP  gene,
E14Tg2a  ESCs,  and  OP9  cells  were  generated  as  described  previously[12-14]  and
transferred to KAIST.
Generation of EMG7 mouse ESCs expressing tdTomato fluorescence
Lentiviruses were generated by transfecting FUtdTW (Addgene plasmid 22478)[15]
with pMD2.G (Addgene plasmid 12259), pMDLg/pRRE (Addgene plasmid 12251)
and pRSV-Rev (Addgene  plasmid 12253)[16]  in  293T cells  using  jetPEI  (Polypus-
transfection). Supernatants were collected 48 h after transfection, filtered through a
0.45 μm filter, and concentrated by Lenti-X concentrator (Clontech). Viral particles
were resuspended in ESC medium with 4 mg/mL polybrene. EMG7 mouse ESCs
were incubated in this medium for 24 h. Selection of ESCs was performed by FACS
sorting.
Induction of mouse ESC-derived mesodermal precursor cells and CLCs
For the induction of Flk1+ mesodermal precursor cells (MPCs), ESCs were cultured
without leukemia inhibitory factor (LIF, Millipore) and plated on a 0.1% gelatin-
coated  dish  at  a  cell  density  between  1  ×  103  and  1.5  ×  103  cells  cm2  in  the
differentiation medium, which is αMEM (Invitrogen) containing 10% fetal bovine
serum (FBS, Welgene), 0.1 mmol/L of 2-mercaptoethanol (Invitrogen), 2 mmol/L of
L-glutamine  (Invitrogen)  and  50  U/mL  of  penicillin-streptomycin  (Invitrogen).
Medium was changed every other day for 4.5 d. At day 4.5, differentiated ESCs were
harvested  with  0.25%  trypsin-EDTA  (Invitrogen),  and  antigen  retrieval  was
performed in the differentiation medium for 30 min in an incubator. Then, cells were
washed  using  2%  FBS  in  phosphate  buffered  saline  (PBS)  and  incubated  with
biotinconjugated anti–mouse Flk1 antibody (clone AVAS12a1, eBioscience) and anti-
streptavidin MicroBeads (Miltenyi Biotec). Flk1+ MPCs were sorted by AutoMACS
Pro Separator (Miltenyi  Biotec).  For induction of  CLCs,  sorted Flk1+  MPCs were
plated onto the mitomycin C (AG Scientific)-treated confluent OP9 cells at a density of
5-10 × 103 cells cm2 in the medium containing 3 μg/mL of CsA, 10 μmol/L of Y27632,
400 μmol/L of Trolox, and 1 μg/mL of EW7197 (CsAYTE)[11,17].  The medium was
refreshed every other day. Live images of differentiation process of CLCs and CMs
were obtained using Axiovert 200M microscope (Carl Zeiss) equipped with AxioCam
MRm (Carl Zeiss). Phase contrast images including beating CMs were obtained using
an Infinity X digital camera and DpxView LE software (DeltaPix).
Flow cytometry analysis and cell sorting
The cells were harvested with 0.25% trypsin-EDTA or dissociation buffer (Invitrogen).
To analyze live cells, antigen retrieval was performed in the differentiation medium
for 30 min in an incubator and the cells were incubated for 20 min with the following
antibodies: Allophycocyanin-conjugated anti–mouse PDGFRα (eBioscience, 17-1401,
clone APA5, 1:100) and phycoerythrin/Cy7-conjugated anti–mouse Flk1 (BioLegend,
136414,  clone AVAS12a1,  1:50).  In live cell  analysis  and sorting,  dead cells  were
excluded using 4,6-diamidino-2-phenylindole (DAPI, Sigma, D8417, 1:1000), and OP9
cells were excluded from Flk1+ MPC by gating in flow cytometry. The differentiated
CMs were sorted using αMHC-GFP. Analyses and sorting were performed by FACS
Aria II (Beckton Dickinson). Data were analyzed using FlowJo Version 7.5.4 software
(TreeStar).
Animals
Twenty eight male 9-wk-old BALB/c nude mice were kept in the specific pathogen
free before the experiment under a 12:12 h light/dark cycle with lights on at 8:00 AM.
They were deprived of food for 18 h but permitted water ad libitum before surgery.
Animal  care  and experimental  procedures  were  performed to  conform the  NIH
guidelines (Guide for the care and use of laboratory animals) and approved by the
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Animal Care Committee of KAIST (KA2013-40).
Preparation of acute MI model in mouse and cell transplantation
All mice were anesthetized through an intraperitoneal injection of a combination of
anesthetics (80 mg/kg ketamine, 12 mg/kg xylazine) before any procedures. After
intubation, the mice were ventilated with room air (SomnoSuiteTM, Kent scientific).
MI was induced by exposing the heart by left thoracotomy and permanently ligating
the proximal portion of left anterior descending coronary artery with an 8-0 prolene
thread under respiratory support. After ligating the proximal portion of left anterior
descending  coronary  artery,  infarction  of  the  anterior  wall  of  left  ventricle  was
confirmed in each mouse by the presence of a pale anterior wall and myocardial
hypokinesis. Immediately after ligation of coronary artery and the confirmation of
infarction,  100  μL  PBS  containing  1  x  106  PDGFRα+  CLCs  or  αMHC+  CMs were
intramyocardially  injected with a  31-gauge (0.25  mm) insulin  syringe into  the  3
different sites along the borderline of the infarcted area.
Transthoracic echocardiographic analysis
Transthoracic echocardiography (TTE) studies were performed (VIVID 7 dimension
system,  General  Electric-Vingmed  Ultrasound)  15  d  after  MI  surgery  and  cell
implantation. Images were obtained using an i13L transducer (5.3-14.0 MHz, GE
Healthcare) with high temporal and spatial resolution. Two-dimensionally targeted
M-mode parameters were measured at a level of papillary muscle in parasternal short
axis view during 6 consecutive cardiac beats. All measurements were performed in a
blind fashion according to the guidelines of American Society for Echocardiography.
Histologic and morphometric analyses
Before sacrifice, mice were anesthetized with a mixture of ketamine (80 mg/kg) and
xylazine (10 mg/kg). For hematoxylin and eosin (H and E) staining, samples were
fixed overnight with 4% paraformaldehyde and embedded in paraffin after tissue
processing.  For  immunofluorescence  staining,  samples  were  fixed  in  4%
paraformaldehyde, dehydrated in 20% sucrose solution overnight, and embedded in
tissue freezing medium (Leica).  Samples were blocked with 5% goat (or donkey)
serum in 0.01% Trition X-100 in PBS and then incubated overnight at 4 °C with the
following primary antibodies:  Mouse anti-α-actinin monoclonal antibody (Sigma
Aldrich,  A7811,  clone EA-53,  1:100)  or  rabbit  anti-α-actinin  polyclonal  antibody
(Abcam,  ab68167,  clone  EP2529Y,  1:100),  rabbit  anti-Ki-67  polyclonal  antibody
(Abcam, ab15580, 1:200), mouse anti-α-SMA monoclonal antibody (Sigma Aldrich,
A2547,  clone  1A4,  1:500),  hamster  anti-CD31  monoclonal  antibody  (Millipore,
MAB1398Z, clone 2H8, 1:400), and rabbit anti-GFP polyclonal antibody (Millipore,
AB3080, 1:200). After several washes, the samples were incubated for 2 h at RT with
the  following  secondary  antibodies:  Cy5-conjugated  anti-mouse  IgG  (Jackson
ImmunoResearch, 715-175-150, 1:1000) and Cy3-, Cy5-, FITC-conjugated anti-rabbit
IgG antibodies (Jackson ImmunoResearch,  711-165-152,  711-175-152,  711-095-152,
1:1000). Then the samples were mounted with fluorescent mounting medium (DAKO)
and  immunofluorescent  images  were  acquired  using  a  Zeiss  LSM780  confocal
microscope (Carl Zeiss). To calculate capillary density, number of CD31+ endothelial
cells was counted per random 0.5 mm2 area in the infarcted myocardium at 15 d after
cell implantation. To analyze the regenerative effects of host myocardium, number of
Ki-67+/α-actinin+ CMs was counted per 104 nuclei in the peri-infarcted area, ranged
within 200 μm from infarcted region, at 3 and 15 d after cell implantation. Images
were analyzed using ImageJ software (http://imagej.nih.gov/ij/, 1.47V, NIH, United
States).
Statistical analysis
Values are presented as mean ± SD. For continuous data, statistical significance was
determined with the Mann-Whitney U test between 2 groups and the Kruskal-Wallis
test followed by Tukey’s honest significant difference test with ranks or multiple-
group comparison. Statistical analysis was performed with SAS 9.4 (SAS Institute Inc).
Statistical significance was set at P < 0.05 or 0.01.
RESULTS
Implantation  of  PDGFRα+  CLCs  and  αMHC+  CMs equally  improves  contractile
function and structure in infarcted heart
To investigate the regenerative potential of PDGFRα+ CLCs and αMHC+ CMs, cells
were  sorted,  and  approximately  1  ×  106  of  each  were  implanted  into  the  left
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ventricular myocardium after inducing acute MI. The results of the recipient groups
were  compared  with  those  of  MI  hearts  without  implantation.  Analyses  were
performed at 2 wk after implantation of cells (Figure 1A). To trace the implanted cells
in the infarcted heart, we induced PDGFRα+ CLCs from ESCs expressing tdTomato
fluorescence (Figure 1B). As shown in Figure 1C, the implanted cells were mainly
distributed along several myocardial cavities 1 h after implantation.
First, to evaluate the functional recovery of infarcted hearts after cell implantation,
we performed TTE 14 d after implantation. Compared with that in untreated MI
hearts,  the  anterior  and  septal  regional  wall  motion  was  notably  and  similarly
improved (see arrowheads in Figure 2A) in the MI hearts implanted with PDGFRα+
CLCs (hereafter designated as MI+PDGFRα+ CLCs) and αMHC+ CMs (designated as
MI+αMHC+ CMs). Moreover, the left ventricular internal dimension during systole of
both MI+PDGFRα+  CLCs and MI+αMHC+  CMs was approximately 12%–23% less
compared with that of untreated MI hearts (Figure 2B). Both MI+PDGFRα+ CLCs and
MI+αMHC+  CMs also  showed significant  and  similar  improvements  in  systolic
functional parameters, which included an ejection fraction increased by 20.0/15.6%
and fractional shortening increased by 9.5/7.2%, respectively, compared with those of
untreated MI hearts (Figure 2C).  All  TTE parameters are summarized in Table 1.
These findings indicate that the implantation of PDGFRα+ CLCs and αMHC+ CMs had
similar beneficial effects in the functional recovery of acutely infarcted hearts. Next, to
confirm  whether  the  implanted  cells  were  properly  engrafted  to  the  infarcted
myocardium, we performed histologic analyses at 15 d after implantation. Overall, the
gross sizes of MI+PDGFRα+ CLCs and MI+αMHC+ CMs were smaller than that of
untreated  MI  hearts  (Figure  2D).  Hematoxylin  and  eosin  staining  showed  that
untreated MI hearts had a thinner ventricular wall (0.19 mm) than did controls, while
the ventricular walls of MI+PDGFRα+  CLCs and MI+αMHC+  CMs were similarly
thicker (0.47 mm and 0.39 mm, respectively) compared with that of untreated MI
hearts (Figures 2E and F).
Integration, differentiation, proliferation, and survival of implanted PDGFRα+ CLCs
in the infarcted heart
Importantly,  implanted  PDGFRα+  CLCs  and  αMHC+  CMs  were  visible  as
tdTomato+/α-MHC-GFP+  cells aligned and integrated with host CMs (Figure 3A).
Implanted  PDGFRα+  CLCs  and αMHC+  CMs were  mostly  differentiated  into  α-
actinin+ CMs, and they did not convert into CD31+ endothelial cells or αSMA+ mural
cells  (Figures  3B  and  C).  Moreover,  CD31+  blood  vessels  in  the  infracted  area
increased by 2.1- and 1.8-fold in MI+PDGFRα+ CLCs and MI+αMHC+ CMs at day 15
after  implantation  (Figures  4A  and  B),  while  the  numbers  of  Ki-67+  CMs  also
transiently increased equally by 2.4-fold at day 3; no such increases were detected at
day  15  in  both  groups  (Figures  4C  and  D).  Thus,  in  addition  to  integration  of
implanted MI+PDGFRα+  CLCs and MI+αMHC+  CMs into the host  myocardium,
paracrine  effects  of  MI+PDGFRα+  CLCs  and  MI+αMHC+  CMs  appeared  to  be
involved  in  the  functional  recovery  of  acutely  infarcted  hearts.  Both  types  of
implanted cells persisted up to 60 d after implantation (Figure 4E), which was the
longest observation period in this study.
DISCUSSION
In the present study, we demonstrated the regenerative potential  of mouse ESC-
derived PDGFRα+ CLCs in a murine MI model. Implantation of PDGFRα+ CLCs and
αMHC+ CMs equally improved the contractile function and structure in the infarcted
heart. Notably, implanted PDGFRα+ CLCs were well integrated with host CMs and
mostly differentiated into CMs.
Various transcription factors and cell-surface markers of cardiac progenitors or
CLCs have been identified in previous studies[6].  Our group developed PDGFRα+
CLCs  induced  by  CsAYTE,  which  significantly  enhanced  the  commitment  of
mesodermal cells to CLCs; in addition, the PDGFRα+ CLCs can spontaneously further
differentiate into CMs without additional manipulation or stimulation under in vitro
conditions[11].  However,  there  are  few  studies  regarding  the  engraftment  and
regenerative potential of cardiac progenitors or CLCs compared with differentiated
CMs after implantation under in vivo pathologic conditions[18,19]. Takeda et al[7] recently
found that human iPSC-derived CM-fated progenitors from a subpopulation of kinase
insert domain receptor (KDR)+ and PDGFRα+ cells express CD82[7]. Consistent with
our findings, purified CD82+ cells gave rise to CMs under both in vitro and in vivo
conditions[7]. Interestingly, CD82+ cells showed considerably greater engraftment than
differentiated vascular cell adhesion molecule 1 (VCAM1)+ CMs after transplantation
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Figure 1
Figure 1  Implantations of platelet-derived growth factor receptor-α+ cardiac lineage-committed cells and αMHC+ cardiomyocytes in the acute myocardial
infarction murine model. A: Experimental scheme of implanting either platelet-derived growth factor receptor-α (PDGFRα)+ cardiac lineage-committed cells (CLCs)
or αMHC+ cardiomyocytes (CMs) into acute myocardial infarction (MI) murine model. Analyses were performed at 2 wk after implantation of approximately 1 × 106
cells of PDGFRα+ CLCs or αMHC+ CMs into the left ventricular myocardium of acute MI murine model; B: Live cell image showing tdTomato+ cells during induction of
PDGFRα+ CLCs from embryonic stem cells. Scale bars, 100 μm; C: Representative confocal image showing implanted tdTomato+ PDGFRα+ CLCs in the myocardial
spaces (arrowheads) of the infarcted zone (dotted line and arrow), which was formed by ligation of coronary artery 1 h prior to the implantation. Scale bar, 500 μm.
CLCs: Cardiac lineage-committed cells; CMs: Cardiomyocytes; PSCs: Pluripotent stem cells; ESCs: Embryonic stem cells; LIF: Leukemia inhibitory factor.
to the subrenal space[7]. These data indicated that the proliferative capacity of CLCs is
higher than that of differentiated CMs under in vivo conditions. Furthermore, CD82+
cells primarily differentiated into CMs within infarcted hearts at approximately 95%
efficiency;  nevertheless,  there  were  no  data  related  to  functional  and structural
recovery in the infarcted hearts[7]. The LIM-homeodomain transcription factor ISL1 is
the most well-known marker of cardiac progenitors, and recent studies demonstrated
that ISL1+  cardiac progenitors also exhibit  regenerative potential  in the infarcted
heart[20,21]. Another developed strategy, direct reprogramming, was used to generate
proliferative  induced  cardiac  progenitors  from fibroblasts  with  cardiac-specific
transcription  factors  (Mesp1,  Tbx5,  Gata4,  Nkx2.5,  and  Baf60c),  and  these
reprogrammed  cells  were  revealed  to  have  regenerative  potential  in  MI[22,23].
Collectively, the previous and current data provide compelling evidence that cardiac
progenitors or CLCs are potential cellular resources for cardiac regeneration.
However,  our  data  failed  to  demonstrate  the  superior  regenerative  effect  of
proliferative  PDGFRα+  CLCs  compared  with  differentiated  αMHC+  CMs  after
implantation, consistent with a previous report[19]. Although PDGFRα+ CLCs exhibit
more proliferative capacity than differentiated αMHC+ CMs, their expansion might be
restricted owing to the limited space of the myocardium, especially in a small mouse
model. Further experiments using large animal models, such as swine or non-human
primates, might be necessary to confirm the regenerative effect of CLCs. In addition,
the pathologic microenvironment of damaged heart might affect the proliferation and
survival of implanted cells. Indeed, the previous and current data demonstrated that
the engraftment of implanted CLCs and CMs was gradually decreased with time.
Despite  suboptimal  engraftment  and  eventual  death  of  the  implanted  cells  in
infarcted myocardium, the regenerative effect of implanted cells might result from
differential paracrine effects[24]. Recent data demonstrated the significant upregulation
of promigratory, proangiogenic, and antiapoptotic gene expression in the infarcted
myocardium of groups treated with CMs compared with groups treated with PSCs
and the controls[24]. Our data also revealed enhanced angiogenesis after implantation
of  PDGFRα+  CLCs  and  αMHC+  CMs.  Therefore,  the  previous  and  current  data
suggested that not only direct integration but also the paracrine effect of implanted
CLCs and CMs contributes to cardiac regeneration[24]. Further studies are needed to
better understand the therapeutic mechanisms following transplantation of CLCs and
to enhance engraftment.
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Table 1  Echocardiographic parameters of Control, MI, MI+PDGFRα+ CLCs, and MI+αMHC+ CMs groups
Group
LVIDd LVIDs IVSd IVSs LVPWd LVPWs LVEDV LVESV LVSV LVEF FS
(mm) (mm) (mm) (mm) (mm) (mm) (mL) (mL) (mL) (%) (%)
Control 4.46 ± 0.23 3.14 ± 0.14 0.76 ± 0.07 1.08 ± 0.05 0.76 ± 0.10 1.11 ± 0.07 0.22 ± 0.04 0.08 ± 0.01 0.14 ± 0.03 62.7 ± 2.52 29.2 ± 1.72
(n = 7)
MI 5.57 ± 0.60 5.09 ± 0.54 0.67 ± 0.04 0.71 ± 0.07 0.74 ± 0.09 1.03 ± 0.17 0.42 ± 0.14 0.32 ± 0.10 0.10 ± 0.03 22.5 ± 2.91 8.61 ± 1.12
(n = 7)
MI+PDGFRα+
CLCs
4.96 ± 0.38 3.92b ± 0.54 0.68 ± 0.10 0.87 ± 0.27 0.68 ± 0.06 0.99 ± 0.13 0.21b ± 0.14 0.12b ± 0.08 0.09 ± 0.06 42.4b ± 4.38 18.1b ± 2.54
(n = 7)
MI+αMHC+ CMs 5.15 ± 0.56 4.38 ± 0.60 0.65 ± 0.04 0.69 ± 0.04 0.74 ± 0.07 1.08 ± 0.12 0.28a ± 0.14 0.18b ± 0.10 0.10 ± 0.05 38.1b ± 6.86 15.8b ± 4.79
(n = 7)
aP < 0.05 vs MI.
bP < 0.01 vs MI. 
The parameters present as mean ± SD. LVIDd: Left ventricular internal diameter diastole; LVIDs: Left ventricular internal dimension
systole; IVSd: Interventricular septal diastole; IVSs: Interventricular septal systole; LVPWd: Left ventricular posterior wall diameter diastole; LVPWs: Left
ventricular posterior wall diameter systole; LVEDV: Left ventricular end diastolic volume; LVESV: Left ventricular end systolic volume; LVSV: Left
ventricular  stroke  volume;  LVEF:  Left  ventricular  ejection  fraction;  FS:  Fractional  shortening;  CLCs:  Cardiac  lineage-committed  cells;  CMs:
Cardiomyocytes; MI: Myocardial infarction.
Proper electromechanical integration of PSC-derived CMs into host myocardium is
crucial  for  preventing fatal  arrhythmia after  transplantation[1].  In a  recent  study,
Chong et al[25] reported remuscularization of infarcted myocardium after injection of
human ESC-derived CMs into non-human primate models of  MI[26].  These grafts
formed electromechanical junctions with the host myocardium and beat in synchrony,
but ventricular arrhythmias were noted after transplantation[25]. Another recent study
showed that monkey iPSC-derived CMs improved cardiac contractile function after
transplantation into infarcted monkey hearts; nonetheless, the incidence of ventricular
tachycardia was transiently but significantly increased[27]. In our study, we could not
evaluate the occurrence of ventricular arrhythmia because of the technical difficulties
associated with the  mouse model.  Therefore,  further  studies  using large animal
models might be necessary to confirm the arrhythmogenic effect of proliferating CLCs
compared with differentiated CMs after transplantation into infarcted heart.
In conclusion, PDGFRα+ CLCs served as the potential donor population for cardiac
regeneration, and our findings provide conceptual and technical advances in stem cell
therapy for cardiac regeneration.
WJSC https://www.wjgnet.com January 26, 2019 Volume 11 Issue 1
Hong SP et al. PDGFRα+ cardiac lineage cells in MI
50
Figure 2
Figure 2  Implantations of platelet-derived growth factor receptor-α+ cardiac lineage-committed cells and αMHC+ cardiomyocytes equally improves
contractile function and structure in the infarcted heart. A: Representative M-mode transthoracic echocardiography views of control, myocardial infarction (MI),
MI+ platelet-derived growth factor receptor-α (PDGFRα)+ cardiac lineage-committed cells (CLCs), and MI+αMHC+ cardiomyocytes (CMs). Improved anterior (white
arrowheads) and septal (yellow arrowheads) regional wall motion are observed in the left ventricles of MI+PDGFRα+ CLCs and MI+αMHC+ CMs; B and C:
Quantifications of left ventricular internal dimension in systole (mm), ejection fraction (%) and fractional shortening (%). Each group, n = 7. aP < 0.05 and bP < 0.01 vs
Con; cP < 0.01 vs MI; D: Gross images of hearts in control, MI, MI+PDGFRα+ CLCs, and MI+αMHC+ CMs. Scale bars, 2.5 mm; E: H and E staining of mid-sectioned
hearts of control, MI, MI+PDGFRα+ CLCs, and MI+αMHC+ CMs. Scale bars, 1 mm and 50 μm in the upper and lower panels, respectively; F: Quantifications of the
thickness (mm) of left ventricle in the infarcted region. Each group, n = 7. bP < 0.01 vs Con; cP < 0.01 vs MI or MI+PDGFRα+ CLCs. CLCs: Cardiac lineage-committed
cells; CMs: Cardiomyocytes; MI: Myocardial infarction.
Figure 3
Figure 3  Integration and differentiation of implanted platelet-derived growth factor receptor-α+ cardiac lineage-committed cells in the infarcted heart. A:
tdTomato-tagged platelet-derived growth factor receptor-α (PDGFRα)+ cardiac lineage-committed cells (CLCs) or αMHC+ cardiomyocytes (CMs) were implanted into
the infracted myocardium and integration was confirmed by immunostaining. tdTomato+/α-MHC-GFP+ cells (white arrowheads) are implanted PDGFRα+ CLCs and
αMHC+ CMs. Scale bars, 100 μm; B: Representative confocal images showing differentiation of tdTomato+ PDGFRα+ CLCs and αMHC+ CMs into cardiomyocytes 15
d after the implantation. αSMA-expressing cells were negative for tdTomato or α-MHC-GFP signal as shown in the inlet. Scale bars, 25 μm; C: Percentages of α-
actinin+ CMs, CD31 endothelial cells and αSMA+ smooth muscle cells of the implanted PDGFRα+ CLCs and αMHC+ CMs. Each group, n = 4. Scale bars, 20 μm.
CLCs: Cardiac lineage-committed cells; CMs: Cardiomyocytes; MI: Myocardial infarction; ECs: Endothelial cells; SMCs: Smooth muscle cells.
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Figure 4
Figure 4  Proliferation and survival of implanted platelet-derived growth factor receptor-α+ cardiac lineage-committed cells in the infarcted heart. A:
Representative confocal image of Ki-67+ host cardiomyocytes in the peri-infarcted region 3 d after cell injection. Dotted-lined rectangular region is magnified in right.
Scale bar, 50 μm; B: Quantifications of Ki-67+α-actinin+ cardiomyocytes per 104 nuclei in the peri-infarcted region 3 and 15 d after the implantation. Each group, n = 4.
aP < 0.05 vs myocardial infarction (MI); C: Representative confocal images of revascularization within the infarcted areas 15 d after the implantation. Scale bars, 100
μm; D: Quantifications of capillary density (No. of CD31+ ECs/mm2) within the infarcted areas. Each group, n = 4. bP < 0.01 vs MI; cP < 0.01 vs MI+ platelet-derived
growth factor receptor-α (PDGFRα)+ cardiac lineage-committed cells (CLCs); E: Representative confocal images of tdTomato+ PDGFRα+ CLCs and αMHC+ CMs 60
d after the implantation. Three independent experiments showed similar findings. Scale bars, 20 μm; F: Schematic diagram illustrating the regenerative potential of
PDGFRα+ CLCs in the infarcted heart. CLCs: Cardiac lineage-committed cells; CMs: Cardiomyocytes; MI: Myocardial infarction.
ARTICLE HIGHLIGHTS
Research background
Pluripotent  stem  cell  (PSC)-derived  cardiomyocytes  (CMs)  have  become  one  of  the  most
attractive cellular resources for cell-based therapy to rescue damaged cardiac tissue.
Research motivation
The  proliferative  capacity  of  PSC-derived  CMs  is  decreased  after  beating  and  terminal
differentiation. Furthermore, there is no definite surface marker of differentiated PSC-derived
CMs to facilitate purification.
Research objectives
We investigated the regenerative potential of mouse embryonic stem cell-derived PDGFRα+
cardiac lineage-committed cells  (CLCs)  in a  murine myocardial  infarction (MI)  model  and
compared their efficacy with differentiated CMs.
Research methods
We implanted platelet-derived growth factor receptor-α (PDGFRα)+ CLCs and differentiated
αMHC+ CMs into a MI murine model and performed functional analysis using transthoracic
echocardiography (TTE) and histologic analysis.
Research results
Compared with the untreated MI hearts,  the anterior and septal  regional  wall  motion and
systolic functional parameters were notably and similarly improved in the MI hearts implanted
with PDGFRα+ CLCs and αMHC+ CMs based on TTE. In histologic analysis, the untreated MI
hearts contained a thinner ventricular wall than did the controls, while the ventricular walls of
MI hearts implanted with PDGFRα+ CLCs and αMHC+ CMs were similarly thicker compared
with that of  the untreated MI hearts.  Furthermore,  implanted PDGFRα+  CLCs aligned and
integrated with host CMs and were mostly differentiated into α-actinin+ CMs, and they did not
convert into CD31+ endothelial cells or αSMA+ mural cells.
Research conclusions
PDGFRα+ CLCs from mouse ESCs exhibiting proliferative capacity showed a regenerative effect
in infarcted myocardium. Therefore,  mouse ESC-derived PDGFRα+  CLCs may represent  a
potential cellular resource for cardiac regeneration.
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Research perspectives
PDGFRα+  CLCs served as the potential donor population for cardiac regeneration, and our
findings provide conceptual and technical advances in stem cell therapy for cardiac regeneration.
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